George S Baillie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8363405/publications.pdf

Version: 2024-02-01

193 papers	12,388 citations	20817 60 h-index	30087 103 g-index
199 all docs	199 docs citations	199 times ranked	12122 citing authors

#	Article	IF	Citations
1	Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins. Journal of Molecular and Cellular Cardiology, 2022, 165, 86-102.	1.9	11
2	CMYA5 is a novel interaction partner of FHL2 in cardiac myocytes. FEBS Journal, 2022, 289, 4622-4645.	4.7	6
3	<scp>SUMOylation</scp> does not affect cardiac troponin I stability but alters indirectly the development of force in response to Ca²⁺. FEBS Journal, 2022, 289, 6267-6285.	4.7	2
4	The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Science OA, 2021, 7, FSO650.	1.9	23
5	The RanBP2/RanGAP1-SUMO complex gates Î²-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis. Oncogene, 2021, 40, 2243-2257.	5.9	13
6	Identification and Characterization of an Affimer Affinity Reagent for the Detection of the cAMP Sensor, EPAC1. Cells, 2021, 10, 2307.	4.1	1
7	Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 2021, 16, e0260283.	2.5	1
8	Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 677-688.	7.1	8
9	Post-translational regulation of cardiac myosin binding protein-C: A graphical review. Cellular Signalling, 2020, 76, 109788.	3.6	16
10	Dynamic Palmitoylation of the Sodium-Calcium Exchanger Modulates Its Structure, Affinity for Lipid-Ordered Domains, and Inhibition by XIP. Cell Reports, 2020, 31, 107697.	6.4	32
11	Structural insights into TAZ2 domainâ€“mediated CBP/p300 recruitment by transactivation domain 1 of the lymphopoietic transcription factor E2A. Journal of Biological Chemistry, 2020, 295, 4303-4315.	3.4	9
12	Epidermal growth factor signaling through transient receptor potential melastatin 7 cation channel regulates vascular smooth muscle cell function. Clinical Science, 2020, 134, 2019-2035.	4.3	15
13	Phosphodiesterase 4B: Master Regulator of Brain Signaling. Cells, 2020, 9, 1254.	4.1	36
14	Fibrin Breakdown Assay. Bio-protocol, 2020, 10, e3585.	0.4	1
15	Measuring cAMP Specific Phosphodiesterase Activity: A Two-step Radioassay. Bio-protocol, 2020, 10, e3581.	0.4	0
16	Investigation of Novel Cavin-1/Suppressor of CytokineÂSignaling 3 (SOCS3) Interactions by Coimmunoprecipitation, Peptide Pull-Down, and Peptide Array Overlay Approaches. Methods in Molecular Biology, 2020, 2169, 105-118.	0.9	2
17	Therapeutic targeting of 3â€²,5â€²-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nature Reviews Drug Discovery, 2019, 18, 770-796.	46.4	205
18	The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumourâ€™s TMPRSS2-ERG Fusion Status. Prostate Cancer, 2019, 2019, 1-14.	0.6	8

#	Article	IF	Citations
19	Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13320-13329.	7.1	54
20	A high-fat diet promotes depression-like behavior in mice by suppressing hypothalamic PKA signaling. Translational Psychiatry, 2019, 9, 141.	4.8	77
21	AKAP95 Organizes a Nuclear Microdomain to Control Local cAMP for Regulating Nuclear PKA. Cell Chemical Biology, 2019, 26, 885-891.e4.	5.2	37
22	Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A â€“ C-Raf. BMC Cancer, 2019, 19, 266.	2.6	14
23	Phosphorylation of PDE4A5 by MAPKAPK2 attenuates fibrin degradation via p75 signalling. Journal of Biochemistry, 2019, 166, 97-106.	1.7	7
24	Methods to Investigate Arrestins in Complex with Phosphodiesterases. Methods in Molecular Biology, 2019, 1957, 121-137.	0.9	1
25	PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders. Cellular Signalling, 2019, 60, 31-38.	3.6	4
26	Effect of tacrolimus on skin microbiome in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1400-1406.	5.7	16
27	Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes. Biochemical Society Transactions, 2019, 47, 1405-1414.	3.4	16
28	Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches. Biochemical Society Transactions, 2019, 47, 1557-1565.	3.4	36
29	Interaction of suppressor of cytokine signalling 3 with cavin-1 links SOCS3 function and cavin-1 stability. Nature Communications, 2018, 9, 168.	12.8	25
30	FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system. Molecular Psychiatry, 2018, 23, 1278-1286.	7.9	31
31	Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. European Urology Focus, 2018, 4, 376-384.	3.1	12
32	Amyloid Î² synaptotoxicity is Wntâ€PCP dependent and blocked by fasudil. Alzheimer's and Dementia, 2018, 14, 306-317.	0.8	81
33	Increase in Ca2+ current by sustained cAMP levels enhances proliferation rate in GH3 cells. Life Sciences, 2018, 192, 144-150.	4.3	6
34	A769662 Inhibits Insulin-Stimulated Akt Activation in Human Macrovascular Endothelial Cells Independent of AMP-Activated Protein Kinase. International Journal of Molecular Sciences, 2018, 19, 3886.	4.1	9
35	Modelling and mathematical analysis of the M$_{2}$ receptor-dependent joint signalling and secondary messenger network in CHO cells. Mathematical Medicine and Biology, 2018, 35, 279-297.	1.2	0
36	A role for APP in Wnt signalling links synapse loss with Î²-amyloid production. Translational Psychiatry, 2018, 8, 179.	4.8	74

#	Article	IF	Citations
37	A biochemical and genetic discovery pipeline identifies PLCÎ´4b as a nonreceptor activator of heterotrimeric G-proteins. Journal of Biological Chemistry, 2018, 293, 16964-16983.	3.4	20
38	PDE4-Mediated cAMP Signalling. Journal of Cardiovascular Development and Disease, 2018, 5, 8.	1.6	54
39	RAB40C regulates RACK1 stability via the ubiquitinâ€“proteasome system. Future Science OA, 2018, 4, FSO317.	1.9	18
40	The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Prostate Cancer, 2018, 2018, 1-11.	0.6	10
41	Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1â€“42â€mediated cytotoxicity. FEBS Open Bio, 2017, 7, 64-73.	2.3	13
42	Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners. Biochemical Journal, 2017, 474, 597-609.	3.7	27
43	TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. Cancer Cell, 2017, 31, 621-634.e6.	16.8	73
44	Molecular mechanism of GÎ±i activation by non-GPCR proteins with a GÎ±-Binding and Activating motif. Nature Communications, 2017, 8, 15163.	12.8	39
45	Cardiac cAMP Microdomains and Their Modulation Using Disruptor Peptides. Cardiac and Vascular Biology, 2017, , 161-173.	0.2	0
46	Peptide array-based screening reveals a large number of proteins interacting with the ankyrin-repeat domain of the zDHHC17 S-acyltransferase. Journal of Biological Chemistry, 2017, 292, 17190-17202.	3.4	33
47	PDE8 controls CD4+ T cell motility through the PDE8A-Raf-1 kinase signaling complex. Cellular Signalling, 2017, 40, 62-72.	3.6	12
48	RACK1 stabilises the activity of PP2A to regulate the transformed phenotype in mammary epithelial cells. Cellular Signalling, 2017, 35, 290-300.	3.6	7
49	Ambra1 spatially regulates Src activity and Src/FAK-mediated cancer cell invasion via trafficking networks. ELife, 2017, 6, .	6.0	32
50	PTEN controls glandular morphogenesis through a juxtamembrane Î²-Arrestin1/ARHGAP21 scaffolding complex. ELife, 2017, 6, .	6.0	19
51	PDE2A2 regulates mitochondria morphology and apoptotic cell death via local modulation of cAMP/PKA signalling. ELife, 2017, 6, .	6.0	82
52	Epsteinâ€“Barr virus nuclear antigen 1 interacts with regulator of chromosome condensation 1 dynamically throughout the cell cycle. Journal of General Virology, 2017, 98, 251-265.	2.9	15
53	Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS. Anticancer Research, 2017, 37, 3833-3839.	1.1	14
54	Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1. ELife, 2016, 5, .	6.0	191

#	Article	IF	Citations
55	Editorial: Frontiers in the Pharmacological Manipulation of Intracellular cAMP Levels. Frontiers in Pharmacology, 2016, 7, 4.	3.5	1
56	Gpr161 anchoring of PKA consolidates GPCR and cAMP signaling. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7786-7791.	7.1	86
57	Non-genetic therapeutic approaches to Canavan disease. Journal of the Neurological Sciences, 2016, 366, 116-124.	0.6	13
58	SUMOylation of DISC1: A Potential Role in Neural Progenitor Proliferation in the Developing Cortex. Molecular Neuropsychiatry, 2016, 2, 20-27.	2.9	4
59	Location, location, location: PDE4D5 function is directed by its unique N-terminal region. Cellular Signalling, 2016, 28, 701-705.	3.6	9
60	Interaction between integrin Î±5 and PDE4D regulates endothelial inflammatory signalling. Nature Cell Biology, 2016, 18, 1043-1053.	10.3	79
61	Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory. Journal of Neuroscience, 2016, 36, 8936-8946.	3.6	52
62	Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling. Science Signaling, 2016, 9, ra109.	3.6	80
63	Missense mutation in DISC1 C-terminal coiled-coil has GSK3Î² signaling and sex-dependent behavioral effects in mice. Scientific Reports, 2016, 6, 18748.	3.3	26
64	Editorial. Cellular Signalling, 2016, 28, 699-700.	3.6	0
65	p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. Cell Reports, 2016, 14, 255-268.	6.4	42
66	Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition. Neuropsychopharmacology, 2016, 41, 1080-1092.	5.4	53
67	Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. Oncotarget, 2016, 7, 70669-70684.	1.8	21
68	3â€…Angiotensin 1â€“7 regulation of endothelin-1 system in pulmonary hypertension. Heart, 2015, 101, A1.3-A1.	2.9	0
69	George Baillie on peptide array, a technique that transformed research on phosphodiesterases. Future Science OA, 2015, 1, FSO27.	1.9	4
70	Heat shock protein 20 (HSP20) is a novel substrate for protein kinase D1 (PKD1). Cell Biochemistry and Function, 2015, 33, 421-426.	2.9	10
71	Cytodynamics and endpoint selection for a reliable in vitro assessment of nanoneurotoxicity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 407-408.	3.3	2
72	Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains. Cellular Signalling, 2015, 27, 756-769.	3.6	34

#	Article	IF	Citations
73	Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2. Circulation Research, 2015, 117, 707-719.	4.5	105
74	Phosphorylation of ezrin on Thr567 is required for the synergistic activation of cell spreading by EPAC1 and protein kinase A in HEK293T cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 1749-1758.	4.1	15
75	The activity of cAMPâ€phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase Aâ€dependent phosphorylation within its unique Nâ€terminus. FEBS Letters, 2015, 589, 750-755.	2.8	18
76	Small heat shock protein 20 (Hsp20) facilitates nuclear import of protein kinase D 1 (PKD1) during cardiac hypertrophy. Cell Communication and Signaling, 2015, 13, 16.	6.5	28
77	The role and therapeutic targeting of Î±-, Î²- and Î³-secretase in Alzheimer's disease. Future Science OA, 2015, 1, FSO11.	1.9	75
78	UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy. Cellular Signalling, 2015, 27, 908-922.	3.6	29
79	Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression. British Journal of Cancer, 2015, 113, 1502-1511.	6.4	20
80	Acetylcholinesterase activity as a neurotoxicity marker within the context of experimentally-simulated hyperprolinaemia: An in vitro approach. Journal of Natural Science, Biology and Medicine, 2015, 6, 98.	1.0	8
81	The cardioprotective role of small heat-shock protein 20. Biochemical Society Transactions, 2014, 42, 270-273.	3.4	17
82	Targeted disruption of the heat shock protein 20â€“phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy. FEBS Open Bio, 2014, 4, 923-927.	2.3	30
83	Epidermal Growth Factor Receptor substrate 8 (Eps8) controls Src/FAK-dependent phenotypes in squamous carcinoma cells. Journal of Cell Science, 2014, 127, 5303-16.	2.0	21
84	Î²-Adrenergic modulation of myocardial conduction velocity: Connexins vs. sodium current. Journal of Molecular and Cellular Cardiology, 2014, 77, 147-154.	1.9	25
85	Real-time probing of Î²-amyloid self-assembly and inhibition using fluorescence self-quenching between neighbouring dyes. Molecular BioSystems, 2014, 10, 34-44.	2.9	37
86	PKA phosphorylation of p62/SQSTM1 regulates PB1 domain interaction partner binding. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2765-2774.	4.1	37
87	Phosphodiesterase 4 interacts with the 5-HT4(b) receptor to regulate cAMP signaling. Cellular Signalling, 2014, 26, 2573-2582.	3.6	14
88	Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis. Cellular Signalling, 2014, 26, 2446-2459.	3.6	56
89	A biosensor to monitor dynamic regulation and function of tumour suppressor PTEN in living cells. Nature Communications, 2014, 5, 4431.	12.8	21
90	Perihaematomal cytokine expression is a crucial component of intracerebral haemorrhage pathophysiology. Neurological Sciences, 2014, 35, 1471-1473.	1.9	1

#	Article	IF	Citations
91	Compartmentalisation of second messenger signalling pathways. Current Opinion in Genetics and Development, 2014, 27, 20-25.	3.3	50
92	Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression. Cellular Signalling, 2014, 26, 1958-1974.	3.6	33
93	The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. British Journal of Cancer, 2014, 110, 1278-1287.	6.4	41
94	The phosphorylation of Hsp20 enhances its association with amyloid-Î² to increase protection against neuronal cell death. Molecular and Cellular Neurosciences, 2014, 61, 46-55.	2.2	19
95	Arrestin-Dependent Localization of Phosphodiesterases. Handbook of Experimental Pharmacology, 2014, 219, 293-307.	1.8	7
96	Arrestin Regulation of Small GTPases. Handbook of Experimental Pharmacology, 2014, 219, 375-385.	1.8	1
97	Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochemical Pharmacology, 2013, 85, 1297-1305.	4.4	17
98	The extent and the nature of the cholinergic contribution to the hepatic encephalopathy-induced cognitive impairment. Free Radical Biology and Medicine, 2013, 65, 1516-1517.	2.9	0
99	Can acetylcholinesterase activity be considered as a reliable biomarker for the assessment of cadmium-induced neurotoxicity?. Food and Chemical Toxicology, 2013, 56, 406-410.	3.6	11
100	RACK(1) to the future â€“ a historical perspective. Cell Communication and Signaling, 2013, 11, 53.	6.5	37
101	Specific interactions between Epac1, Î²-arrestin2 and PDE4D5 regulate Î²-adrenergic receptor subtype differential effects on cardiac hypertrophic signaling. Cellular Signalling, 2013, 25, 970-980.	3.6	48
102	Lanthanum-induced neurotoxicity: solving the riddle of its involvement in cognitive impairment?. Archives of Toxicology, 2013, 87, 2031-2035.	4.2	15
103	Targeting proteinâ€“protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. Future Medicinal Chemistry, 2013, 5, 451-464.	2.3	47
104	Reciprocal regulation of PKA and Rac signaling. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8531-8536.	7.1	42
105	Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1533-42.	7.1	49
106	Cavinâ€1/PTRF as a new substrate of the SOCS3 E3 ubiquitin ligase complex. FASEB Journal, 2013, 27, 782.1.	0.5	0
107	The A-kinase-anchoring protein AKAP-Lbc facilitates cardioprotective PKA phosphorylation of Hsp20 on Ser16. Biochemical Journal, 2012, 446, 437-443.	3.7	42
108	PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects. Biochemical Society Transactions, 2012, 40, 210-214.	3.4	52

#	Article	IF	Citations
109	Protein kinase D in the hypertrophy pathway. Biochemical Society Transactions, 2012, 40, 287-289.	3.4	16
110	cAMP: Novel concepts in compartmentalised signalling. Seminars in Cell and Developmental Biology, 2012, 23, 181-190.	5.0	59
111	Gravin Orchestrates Protein Kinase A and Î²2-Adrenergic Receptor Signaling Critical for Synaptic Plasticity and Memory. Journal of Neuroscience, 2012, 32, 18137-18149.	3.6	54
112	Cyclic AMPâ€specific phosphodiesterase, PDE8A1, is activated by protein kinase Aâ€mediated phosphorylation. FEBS Letters, 2012, 586, 1631-1637.	2.8	31
113	Elucidation of a Structural Basis for the Inhibitor-Driven, p62 (SQSTM1)-Dependent Intracellular Redistribution of cAMP Phosphodiesterase-4A4 (PDE4A4). Journal of Medicinal Chemistry, 2011, 54, 3331-3347.	6.4	34
114	Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110Î³. Molecular Cell, 2011, 42, 84-95.	9.7	174
115	Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)â€“HSP20 complex attenuates the Î²-agonist induced hypertrophic response in cardiac myocytes. Journal of Molecular and Cellular Cardiology, 2011, 50, 872-883.	1.9	94
116	Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation. Biochemical Journal, 2011, 435, 755-769.	3.7	63
117	The emerging role of HSP20 as a multifunctional protective agent. Cellular Signalling, 2011, 23, 1447-1454.	3.6	67
118	Î²-Arrestin 1 Inhibits the GTPase-Activating Protein Function of ARHGAP21, Promoting Activation of RhoA following Angiotensin II Type 1A Receptor Stimulation. Molecular and Cellular Biology, 2011, 31, 1066-1075.	2.3	67
119	The Structure of the Human RNase H2 Complex Defines Key Interaction Interfaces Relevant to Enzyme Function and Human Disease. Journal of Biological Chemistry, 2011, 286, 10530-10539.	3.4	94
120	A Phosphodiesterase 3B-based Signaling Complex Integrates Exchange Protein Activated by cAMP 1 and Phosphatidylinositol 3-Kinase Signals in Human Arterial Endothelial Cells. Journal of Biological Chemistry, 2011, 286, 16285-16296.	3.4	46
121	Small Molecule AKAP-Protein Kinase A (PKA) Interaction Disruptors That Activate PKA Interfere with Compartmentalized cAMP Signaling in Cardiac Myocytes. Journal of Biological Chemistry, 2011, 286, 9079-9096.	3.4	92
122	Distinct functional outputs of PTEN signalling are controlled by dynamic association with Î²-arrestins. EMBO Journal, 2011, 30, 2557-2568.	7.8	58
123	Structure-Function Analysis of Core STRIPAK Proteins. Journal of Biological Chemistry, 2011, 286, 25065-25075.	3.4	136
124	Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. Biochemical Journal, 2010, 428, 55-65.	3.7	35
125	Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 2010, 432, 575-599.	3.7	6
126	Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C. Biochemical Journal, 2010, 432, 207-219.	3.7	28

#	Article	IF	Citations
127	Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 2010, 38, 1058-1061.	3.4	14
128	Receptor dependent cellular uptake of synthetic low density lipoprotein by mammalian cells in serum-free tissue culture. Journal of Pharmacy and Pharmacology, 2010, 58, 1337-1342.	2.4	6
129	A Complex between FAK, RACK1, and PDE4D5 Controls Spreading Initiation and Cancer Cell Polarity. Current Biology, 2010, 20, 1086-1092.	3.9	214
130	p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. Cellular Signalling, 2010, 22, 1576-1596.	3.6	37
131	Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/Î²-Arrestin/cAMP Phosphodiesterase 4 Complex. Molecular and Cellular Biology, 2010, 30, 1660-1672.	2.3	61
132	Cyclic AMP Phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a Vascular Endothelial Cadherin (VE-Cad)-based Signaling Complex and Controls cAMP-mediated Vascular Permeability. Journal of Biological Chemistry, 2010, 285, 33614-33622.	3.4	81
133	Evolutionarily Conserved Role of Calcineurin in Phosphodegron-Dependent Degradation of Phosphodiesterase 4D. Molecular and Cellular Biology, 2010, 30, 4379-4390.	2.3	26
134	Inferring Signaling Pathway Topologies from Multiple Perturbation Measurements of Specific Biochemical Species. Science Signaling, 2010, 3, ra20.	3.6	101
135	MEK1 Binds Directly to Î²Arrestin1, Influencing Both Its Phosphorylation by ERK and the Timing of Its Isoprenaline-stimulated Internalization. Journal of Biological Chemistry, 2009, 284, 11425-11435.	3.4	65
136	Mdm2 directs the ubiquitination of Î²-arrestin-sequestered cAMP phosphodiesterase-4D5.. Journal of Biological Chemistry, 2009, 284, 21776.	3.4	2
137	The Cardiac IKs Potassium Channel Macromolecular Complex Includes the Phosphodiesterase PDE4D3. Journal of Biological Chemistry, 2009, 284, 9140-9146.	3.4	118
138	Mdm2 Directs the Ubiquitination of Î²-Arrestin-sequestered cAMP Phosphodiesterase-4D5. Journal of Biological Chemistry, 2009, 284, 16170-16182.	3.4	59
139	Phosphorylation of RACK1 on Tyrosine 52 by c-Abl Is Required for Insulin-like Growth Factor I-mediated Regulation of Focal Adhesion Kinase. Journal of Biological Chemistry, 2009, 284, 20263-20274.	3.4	89
140	A scanning peptide array approach uncovers association sites within the JNK/Î²arrestin signalling complex. FEBS Letters, 2009, 583, 3310-3316.	2.8	23
141	Sleep deprivation impairs cAMP signalling in the hippocampus. Nature, 2009, 461, 1122-1125.	27.8	339
142	Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS Journal, 2009, 276, 1790-1799.	4.7	192
143	The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagonâ€like peptideâ€1 release. British Journal of Pharmacology, 2009, 157, 633-644.	5.4	50
144	In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10). Cellular Signalling, 2008, 20, 2071-2083.	3.6	17

#	Article	IF	Citations
145	Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). Cellular Signalling, 2008, 20, 2356-2369.	3.6	41
146	Mutations of Î²-arrestin 2 that limit self-association also interfere with interactions with the Î²2-adrenoceptor and the ERK1/2 MAPKs: implications for Î²2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochemical Journal, 2008, 413, 51-60.	3.7	40
147	EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12791-12796.	7.1	109
148	Tyrosine 302 in RACK1 Is Essential for Insulin-like Growth Factor-I-mediated Competitive Binding of PP2A and Î²1 Integrin and for Tumor Cell Proliferation and Migration. Journal of Biological Chemistry, 2008, 283, 22952-22961.	3.4	67
149	Protein Kinase A Type I and Type II Define Distinct Intracellular Signaling Compartments. Circulation Research, 2008, 103, 836-844.	4.5	185
150	Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change. Biochemical Journal, 2008, 411, 361-369.	3.7	26
151	cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular System. Circulation Research, 2007, 100, 950-966.	4.5	283
152	Compartmentalization of cAMP-Dependent Signaling by Phosphodiesterase-4D Is Involved in the Regulation of Vasopressin-Mediated Water Reabsorption in Renal Principal Cells. Journal of the American Society of Nephrology: JASN, 2007, 18, 199-212.	6.1	134
153	Dynamic Regulation, Desensitization, and Cross-talk in Discrete Subcellular Microdomains during Î²2-Adrenoceptor and Prostanoid Receptor cAMP Signaling. Journal of Biological Chemistry, 2007, 282, 34235-34249.	3.4	51
154	PDE4B5, a Novel, Super-Short, Brain-Specific cAMP Phosphodiesterase-4 Variant Whose Isoform-Specifying N-Terminal Region Is Identical to That of cAMP Phosphodiesterase-4D6 (PDE4D6). Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 600-609.	2.5	65
155	Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of Î²-arrestin using spot-immobilized peptide arrays. Biochemical Journal, 2007, 404, 71-80.	3.7	88
156	cAMP-specific phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique non-redundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling. Biochemical Society Transactions, 2007, 35, 938-941.	3.4	39
157	p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. Journal of Cell Biology, 2007, 177, 1119-1132.	5.2	116
158	1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, Î²arrestin and RACK1. Cellular Signalling, 2007, 19, 2612-2624.	3.6	53
159	Reduced PDE4 expression and activity contributes to enhanced catecholamine-induced cAMP accumulation in adipocytes from FOXC2 transgenic mice. FEBS Letters, 2006, 580, 4126-4130.	2.8	20
160	Phosphodiesterase-4 gates the ability of protein kinase A to phosphorylate G-protein receptor kinase-2 and influence its translocation. Biochemical Society Transactions, 2006, 34, 474-475.	3.4	7
161	cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. Biochemical Society Transactions, 2006, 34, 504-509.	3.4	33
162	Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, Î²-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochemical Journal, 2006, 398, 23-36.	3.7	144

#	Article	IF	Citations
163	Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293Î²2 cells and cardiac myocytes. Biochemical Journal, 2006, 394, 427-435.	3.7	35
164	Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. European Journal of Cell Biology, 2006, 85, 673-678.	3.6	52
165	PGE1 stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. Journal of Cell Biology, 2006, 175, 441-451.	5.2	171
166	Î²-Arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of Î²2-adrenoceptor signalling to activation of ERK. Biochemical Society Transactions, 2005, 33, 1333.	3.4	33
167	Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Current Opinion in Cell Biology, 2005, 17, 129-134.	5.4	120
168	Investigation of Extracellular Signal-Regulated Kinase 2 Mitogen-Activated Protein Kinase Phosphorylation and Regulation of Activity of PDE4 Cyclic Adenosine Monophosphate-Specific Phosphodiesterases. , 2005, 307, 225-238.		12
169	RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with Î²Arrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the Î²2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells. Journal of Biological Chemistry, 2005, 280, 33178-33189.	3.4	185
170	Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Letters, 2005, 579, 3264-3270.	2.8	186
171	DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling. Science, 2005, 310, 1187-1191.	12.6	605
172	Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 287, L332-L343.	2.9	100
173	TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling. Journal of Immunology, 2004, 173, 4847-4858.	0.8	123
174	Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyteâ€macrophage differentiation of human U937 cells. British Journal of Pharmacology, 2004, 142, 339-351.	5.4	81
175	Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Biochemical Journal, 2004, 380, 371-384.	3.7	24
176	Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. Cellular Signalling, 2003, 15, 955-971.	3.6	37
177	The Unique Amino-terminal Region of the PDE4D5 cAMP Phosphodiesterase Isoform Confers Preferential Interaction with Î²-Arrestins. Journal of Biological Chemistry, 2003, 278, 49230-49238.	3.4	97
178	Attenuation of the Activity of the cAMP-specific Phosphodiesterase PDE4A5 by Interaction with the Immunophilin XAP2. Journal of Biological Chemistry, 2003, 278, 33351-33363.	3.4	149
179	Â-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates Â-adrenoceptor switching from Gs to Gi. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 940-945.	7.1	356
180	Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochemical Journal, 2003, 370, 429-438.	3.7	52

#	Article	IF	Citations
181	TAPAS-1, a Novel Microdomain within the Unique N-terminal Region of the PDE4A1 cAMP-specific Phosphodiesterase That Allows Rapid, Ca2+-triggered Membrane Association with Selectivity for Interaction with Phosphatidic Acid. Journal of Biological Chemistry, 2002, 277, 28298-28309.	3.4	145
182	Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. Journal of Medical Microbiology, 2002, 51, 344-349.	1.8	310
183	Targeting of Cyclic AMP Degradation to beta 2-Adrenergic Receptors by beta -Arrestins. Science, 2002, 298, 834-836.	12.6	476
184	Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). British Journal of Pharmacology, 2002, 136, 421-433.	5.4	229
185	Phorbol 12-myristate 13-acetate Triggers the Protein Kinase A-Mediated Phosphorylation and Activation of the PDE4D5 cAMP Phosphodiesterase in Human Aortic Smooth Muscle Cells through a Route Involving Extracellular Signal Regulated Kinase (ERK). Molecular Pharmacology, 2001, 60, 1100-1111.	2.3	71
186	Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. British Journal of Pharmacology, 2000, 131, 811-819.	5.4	146
187	ERK2 Mitogen-activated Protein Kinase Binding, Phosphorylation, and Regulation of the PDE4D cAMP-specific Phosphodiesterases. Journal of Biological Chemistry, 2000, 275, 16609-16617.	3.4	215
188	Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. Journal of Antimicrobial Chemotherapy, 2000, 46, 397-403.	3.0	315
189	Role of dimorphism in the development of Candida albicans biofilms. Journal of Medical Microbiology, 1999, 48, 671-679.	1.8	253
190	The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO Journal, 1999, 18, 893-903.	7.8	269
191	Iron-Limited Biofilms of Candida albicans and Their Susceptibility to Amphotericin B. Antimicrobial Agents and Chemotherapy, 1998, 42, 2146-2149.	3.2	87
192	Production of extracellular matrix by Candida albicans biofilms. Journal of Medical Microbiology, 1998, 47, 253-256.	1.8	164
193	A High-fat Diet Promotes Depression-like Behavior in Mice by Suppressing Hypothalamic PKA Signaling. SSRN Electronic Journal, 0, , .	0.4	2